Overview

Exploratory Study of SPD489 in Adults With Major Depressive Disorder (MDD) as Augmentation Therapy to an Antidepressant

Status:
Completed
Trial end date:
2010-08-04
Target enrollment:
0
Participant gender:
All
Summary
To evaluate the efficacy of SPD489 when used as augmentation to an antidepressant in the treatment of major depressive disorder (MDD) as measured by mean change in total Montgomery-Ǻsberg Depression Rating Scale (MADRS) scores.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Shire
Treatments:
Antidepressive Agents
Lisdexamfetamine Dimesylate
Criteria
Inclusion Criteria:

- Adults aged 18-55 with a primary diagnosis of nonpsychotic MDD

Exclusion Criteria:

- History of non-response to multiple antidepressants